[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100583669":3},{"organization":4,"outcomesModule":7,"designInfo":36,"detailedDescription":47,"studyPopulation":21,"armGroups":48,"interventions":75,"overallOfficials":21,"centralContacts":119,"locations":125,"responsibleParty":156,"collaborators":158,"id":171,"slug":172,"hasResults":173,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":21,"eligibilityCriteria":177,"healthyVolunteers":178,"sex":179,"minAge":180,"maxAge":181,"enrollmentInfo":182,"targetDuration":21,"studyType":185,"phases":186,"briefSummary":188,"conditions":189,"keywords":191,"overallStatus":128,"whyStopped":21,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":203},{"fullName":5,"class":6},"PATH","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":28,"otherOutcomes":21},[9,13,15,19,23,26],{"measure":10,"description":11,"timeFrame":12},"Geometric Mean Titers (GMTs) of Anti-circumsporozoite (CS) Immunoglobulin G (IgG) at Baseline and 28 Days after 3rd Vaccine Dose","The anti-CS antibody responses elicited following the primary 3-dose schedule of R21\u002FMM will be assessed in the \"compressed\" (6-10-14 week) immunization schedule and the two \"relaxed\" (2-4-6 month and 3-6-9 month) immunization schedule cohorts.","Baseline and 28 days after 3rd vaccine dose",{"measure":14,"description":11,"timeFrame":12},"Geometric Mean Fold Rise (GMFR) in Anti-CS IgG 28 Days after 3rd Vaccine Dose Compared to Baseline",{"measure":16,"description":17,"timeFrame":18},"Number of Participants with Solicited Adverse Events","Local (redness, swelling, and pain at the injection site) and systemic (fever, drowsiness, irritability, decreased appetite) reactions will be collected in a subset of participants (the first 40 participants in each immunization schedule category at each site).","7 days after each study vaccination",{"measure":20,"description":21,"timeFrame":22},"Number of Participants with Unsolicited Adverse Events",null,"28 days after each study vaccination",{"measure":24,"description":21,"timeFrame":25},"Number of Participants with Serious Adverse Events","Up to 28 days post 4th vaccine dose.",{"measure":27,"description":21,"timeFrame":25},"Number of Participants with Adverse Events of Special Interest",[29,33],{"measure":30,"description":31,"timeFrame":32},"Geometric Mean Titers (GMTs) of Anti-CS IgG Before and 28 Days After 4th Vaccine Dose","The anti-CS antibody responses elicited following the 4th dose of R21\u002FMM will be assessed in the \"compressed\" (6-10-14 week) immunization schedule and the two \"relaxed\" (2-4-6 month and 3-6-9 month) immunization schedule cohorts.","Month 15 predose and 28 days after vaccination",{"measure":34,"description":31,"timeFrame":35},"GMFR in Anti-CS IgG Titer Post 4th Dose Compared to Pre-4th Dose","Month 15 predose and 28 days after 4th dose",{"allocation":37,"interventionModel":38,"interventionModelDescription":21,"primaryPurpose":39,"observationalModel":21,"timePerspective":21,"maskingInfo":40},"RANDOMIZED","PARALLEL","PREVENTION",{"masking":41,"maskingDescription":42,"whoMasked":43},"TRIPLE","964 participants will be randomized to an immunization schedule cohort if eligibility is confirmed by the investigator(s) at 42 to 49 days of age. Both the investigators and parent\u002Flegal guardian will know which cohort their infant has been assigned to.\n\nIn Part A of the study, infants were randomized within each immunization schedule category to receive R21\u002FMM or placebo; neither the blinded study staff nor the parent\u002Flegal guardian knew whether the infant would receive R21\u002FMM or placebo. After the broad introduction of R21\u002FMM for infants from 5 months of age, participants randomized to receive placebo were withdrawn from the study and referred to start R21\u002FMM vaccinations as part of the routine EPI schedule.\n\nIn Part B, only infants randomized to the 6-10-14 week immunization schedule will be further randomized to receive R21\u002FMM or placebo for the primary 3 doses; neither the blinded study staff nor the parent\u002Flegal guardian will know whether the infant will receive R21\u002FMM or placebo.",[44,45,46],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","The R21\u002FMatrix-M (R21\u002FMM) vaccine has been recommended by the World Health Organization (WHO) to prevent clinical malaria in young children living in moderate to high transmission areas of Sub-Saharan Africa. R21\u002FMM is based on the circumsporozoite protein (CSP) targeting the pre-erythrocytic stage of Plasmodium falciparum. R21\u002FMM elicits high levels of antibodies against the central repeat (Asn-Ala-Asn-Pro \\[NANP\\]) of the circumsporozoite protein (CSP) which has been shown to correlate with protection. Currently, R21\u002FMM is recommended to be delivered to young children starting at 5-6 months of age with 3 doses given at monthly intervals, however, there are no existing Essential Programme on Immunization (EPI) vaccine visits scheduled at these ages.\n\nWe plan to evaluate, using the R21\u002FMM malaria vaccine as a model system, how age at first vaccine dose and time intervals between doses modify the immunogenicity of the vaccine.\n\nHealthy male or female infants 6 to 7 weeks of age will be randomized to one of three different immunization schedule cohorts: a) a \"compressed\" conventional schedule at 6-10-14 weeks of age; b) a \"relaxed\" schedule at 2-4-6 months of age; c) a \"relaxed\" schedule at 3-6-9 months of age.\n\nIn the original study design (Part A of the study), participants in each immunization schedule cohort were randomized in a ratio of 3:1 to receive either R21\u002FMM or placebo - up until September 1, 2025, where upon confirmation of R21\u002FMM rollout into the EPI schedule in the study districts, all participants already enrolled in the \"relaxed\" 2-4-6 month and \"relaxed\" 3-6-9 month schedules who had not yet received the first study vaccination, were assigned automatically to receive open-label R21\u002FMM. Recruitment into the study was also paused while the protocol amendment with the revised study design was being developed. At the time of the recruitment being paused, the study had enrolled 644 participants.\n\nAll study participants enrolled during Part A of the study were unblinded as they approached 5 months of age and those who were randomized to the placebo arms had all study procedures discontinued, and were referred to local EPI clinics to receive R21\u002FMM vaccinations and withdrawn from the study. Participants who had been randomized and who had received R21\u002FMM at their first study vaccination, were kept on study and continued to receive open-label R21\u002FMM, as per the protocol.\n\nIn Part B of the study, as per the revised study design, an additional 320 infants will be enrolled and randomized to the \"compressed\" 6-10-14 weeks (Cohort 1), \"relaxed\" 2-4-6 month (Cohort 2) and \"relaxed\" 3-6-9 month (Cohort 3) immunization schedules initially in a 2:1:1 ratio. Participants enrolled into Cohorts 2 and 3 will all be assigned to receive open-label R21\u002FMM, while those enrolled into Cohort 1 will be randomized (blinded) 1:1 to receive 3 doses of either R21\u002FMM or placebo. Once participants in Cohort 1 complete their 28 day post-3rd dose visit, they will be unblinded. Participants randomized to placebo will rollover to a new cohort, Cohort 4, to receive 3 doses of R21\u002FMM on a 5-6-7-month schedule, aligning with WHO guidelines. Participants randomized into the \"relaxed\" 2-4-6 month schedule (Cohort 2) and \"relaxed\" 3-6-9 month schedule (Cohort 3) will receive 3 doses of open-label R21\u002FMM; no placebo participants will be enrolled into Cohorts 2 and 3.\n\nInfants randomized to the respective immunization schedule categories will receive co-administered routine EPI vaccines and participants in all cohorts will receive a 4th dose of R21\u002FMM at Month 15.",[49,62,67,71],{"label":50,"type":51,"description":52,"interventionNames":53},"Compressed 6-10-14 Week Schedule: R21\u002FMM Malaria Vaccine","EXPERIMENTAL","Participants will receive R21\u002FMM malaria vaccination at 6, 10, and 14 weeks of age, co-administered with hexavalent vaccine, pneumococcal conjugate vaccine (PCV), and oral rotavirus vaccine (RV). At 9 months of age participants will receive measles-rubella (MR) vaccine, yellow fever (YF) vaccine, and typhoid conjugate vaccine (TCV).\n\nParticipants will receive a booster dose of R21\u002FMM malaria vaccine at 15 months of age co-administered with Meningococcal (A, C, Y, W, X) Polysaccharide Conjugate Vaccine (MenFive) and the 2nd dose of MR vaccine.",[54,55,56,57,58,59,60,61],"Biological: R21 Matrix-M (R21\u002FMM) Malaria Vaccine","Biological: Hexavalent Vaccine","Biological: Pneumococcal Polysaccharide Conjugate Vaccine","Biological: Rotavirus, Live Attenuated (Oral) Vaccine","Biological: Measles and Rubella Vaccine","Biological: Meningococcal (A, C, Y, W, X) polysaccharide conjugate vaccine","Biological: Yellow Fever vaccine","Biological: Typhoid Conjugate vaccine",{"label":63,"type":6,"description":64,"interventionNames":65},"Compressed 6-10-14 Week Schedule: Placebo \u002F Recommended 5-6-7 Month Schedule: R21\u002FMM Malaria Vaccine","Participants will receive placebo at 6, 10, and 14 weeks of age, co-administered with hexavalent vaccine, PCV, and oral RV. After completion of the 28 day post-Dose 3 visit, these participants will rollover to Cohort 4 (Group 7) to then receive open-label R21\u002FMM vaccine as per the \"recommended\" schedule at 5-6-7 months of age.\n\nAt 9 months of age participants will receive MR and YF vaccines and TCV. Participants will receive a booster dose of R21\u002FMM malaria vaccine at 15 months of age co-administered with the MenFive vaccine and the 2nd dose of MR vaccine.",[54,66,55,56,57,58,59,60,61],"Biological: Placebo",{"label":68,"type":51,"description":69,"interventionNames":70},"Relaxed 2-4-6 Month Schedule: R21\u002FMM Malaria Vaccine","Participants will receive R21\u002FMM malaria vaccination at 2, 4, and 6 months of age co-administered with hexavalent vaccine, PCV, and oral RV. At 9 months of age participants will receive MR and YF vaccines and TCV.\n\nParticipants will receive a booster dose of R21\u002FMM malaria vaccine at 15 months of age co-administered with the MenFive vaccine and the 2nd dose of MR vaccine.",[54,55,56,57,58,59,60,61],{"label":72,"type":51,"description":73,"interventionNames":74},"Relaxed 3-6-9 Month Schedule: R21\u002FMM Malaria Vaccine","Participants will receive R21\u002FMM malaria vaccination at 3, 6, and 9 months of age. Participants will receive the hexavalent vaccine, PCV, and oral RV at 6 weeks, 10 weeks, and 14 weeks of age. At 9 months of age participants will receive MR and YF vaccines and TCV.\n\nParticipants will receive a booster dose of R21\u002FMM malaria vaccine at 15 months of age co-administered with the MenFive vaccine and the 2nd dose of MR vaccine.",[54,55,56,57,58,59,60,61],[76,81,85,91,97,103,107,111,115],{"type":77,"name":78,"description":79,"armGroupLabels":80,"otherNames":21},"BIOLOGICAL","R21 Matrix-M (R21\u002FMM) Malaria Vaccine","Administered by intramuscular injection. Each 0.5 mL dose contains R21 Malaria Antigen (5 mcg) and Matrix-M1 (Adjuvant) (50 mcg).",[63,50,68,72],{"type":77,"name":82,"description":83,"armGroupLabels":84,"otherNames":21},"Placebo","Administered by intramuscular injection. Each dose (0.5 mL) contains Normal saline (0.9%).",[63],{"type":77,"name":86,"description":87,"armGroupLabels":88,"otherNames":89},"Hexavalent Vaccine","Administered by intramuscular injection. Each dose of 0.5 mL contains:\n\n* Diphtheria Toxoid \\> 30 IU\n* Tetanus Toxoid \\> 40 IU\n* B. pertussis (whole cell) \\> 4 IU\n* Hepatitis B surface antigen (HBsAg) (recombinant DNA) 15 mcg\n* Inactivated polio vaccine (Salk strains grown on vero cells): Type - 1 (Mahoney strain) 40 D antigen units (DU); Type - 2 (MEF-1 strain) 8 DU; Type - 3 (Saukett strain) 32 DU\n* Haemophilus influenzae Type b (Hib) Conjugate Vaccine (Adsorbed) polyribosylribitol phosphate (PRP) 10 mcg conjugated to tetanus toxoid (TT) (carrier protein) 19 to 33 mcg\\]",[63,50,68,72],[90],"HEXASIIL",{"type":77,"name":92,"description":93,"armGroupLabels":94,"otherNames":95},"Pneumococcal Polysaccharide Conjugate Vaccine","Administered by intramuscular injection. Each 0.5 mL dose contains 2 mcg each Saccharide for serotypes 1, 5, 9V, 14, 19A, 19F, 23F, 7F, 6A and 4 mcg Saccharide for serotype 6B.",[63,50,68,72],[96],"PNEUMOSIL",{"type":77,"name":98,"description":99,"armGroupLabels":100,"otherNames":101},"Rotavirus, Live Attenuated (Oral) Vaccine","Administered orally. Each 2.0 mL dose contains: Live Attenuated Bovine-Human Rotavirus Reassortant \\[G1, G2, G3, G4 and G9\\], 5.6 focus-forming units (FFU) \u002F serotype.",[63,50,68,72],[102],"ROTASIIL",{"type":77,"name":104,"description":105,"armGroupLabels":106,"otherNames":21},"Measles and Rubella Vaccine","Administered by subcutaneous injection. Each 0.5 mL dose contains not less than 1000 cell culture infectious dose 50% (CCID50) of Measles virus and 1000 CCID50 of Rubella virus.",[63,50,68,72],{"type":77,"name":108,"description":109,"armGroupLabels":110,"otherNames":21},"Meningococcal (A, C, Y, W, X) polysaccharide conjugate vaccine","Administered by intramuscular injection. Each 0.5 mL dose contains 5 mcg of each Meningococcal A, C, Y, W, and X polysaccharide, 7.8 to 33.4 mcg of TT and 11.7 to 50.1 mcg of recombinant CRM197.",[63,50,68,72],{"type":77,"name":112,"description":113,"armGroupLabels":114,"otherNames":21},"Yellow Fever vaccine","Yellow fever vaccine will be locally sourced by each trial site in accordance with the countries' EPI program.",[63,50,68,72],{"type":77,"name":116,"description":117,"armGroupLabels":118,"otherNames":21},"Typhoid Conjugate vaccine","Typhoid conjugate vaccine will be locally sourced by each trial site in accordance with the countries' EPI program.",[63,50,68,72],[120],{"name":121,"role":122,"phone":123,"phoneExt":21,"email":124},"Michael Thigpen, MD","CONTACT","+1 202 822 0033","mthigpen@path.org",[126,143],{"facility":127,"status":128,"city":129,"state":21,"zip":21,"country":130,"countryCode":131,"cosmosGeoPoint":132,"geoPoint":137,"contacts":138},"Institut de Recherche en Sciences de la Santé (IRSS)","RECRUITING","Bobo-Dioulasso","Burkina Faso","BF",{"type":133,"coordinates":134},"Point",[135,136],-4.29489,11.18064,{"lat":136,"lon":135},[139],{"name":140,"role":122,"phone":141,"phoneExt":21,"email":142},"Issaka Zongo, MD, PhD","226 70 78 22 74","zongoissaka08@gmail.com",{"facility":144,"status":128,"city":145,"state":21,"zip":21,"country":130,"countryCode":131,"cosmosGeoPoint":146,"geoPoint":150,"contacts":151},"Groupe de Recherche Action en Santé (GRAS)","Ouagadougou",{"type":133,"coordinates":147},[148,149],-1.53388,12.36566,{"lat":149,"lon":148},[152],{"name":153,"role":122,"phone":154,"phoneExt":21,"email":155},"Sodiomon Sirima, MD, BA, PhD","226 25 35 56 90","s.sirima@gras.bf",{"type":157,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR",[159,162,164,167,169],{"name":160,"class":161},"Pharmassist Ltd","INDUSTRY",{"name":163,"class":161},"Serum Institute of India Pvt. Ltd.",{"name":165,"class":166},"Agilis","UNKNOWN",{"name":168,"class":166},"MCT-CRO",{"name":170,"class":166},"Cytespace","100583669","phase-2-infant-malaria-vaccine-schedule-optimization-100583669",false,"NCT06879327","Infant Malaria Vaccine Schedule Optimization","A Phase 2b Multicenter Randomized, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of R21\u002FMatrix-M Malaria Vaccine in African Infants With Different Immunization Schedules","Inclusion Criteria:\n\n* Signed informed consent or thumb-printed and witnessed informed consent obtained from the parent\u002Flegal guardian of the infant.\n* Infants must have been born full-term (at ≥37 weeks of gestation) and \\> 2500 grams at birth.\n* Immunization schedule Cohorts 1, 2, and 3: Male and female infants 42-49 days (inclusive) of age at time of enrollment.\n* Prior to group randomization, for infants in Cohort 1 randomization to receive vaccine dose 1 (Groups 1 and 2 of R21\u002FMM or placebo, respectively) will occur at 42-49 days of age. Infants in Cohorts 2 and 3 will not be randomized to R21\u002FMM or placebo; placebo will no longer be given. Rather infants in these cohorts will receive open-label R21\u002FMM according to the immunization schedule category to which they have been randomized. Infants in Cohort 2, will receive their open-label R21\u002FMM vaccine dose 1 (Group 3) at 2 months (56-63 days of age). Infants in Cohort 3, will receive their open-label R21\u002FMM vaccine dose 1 (Group 5) at 3 months (84-91 days of age).\n* The participant's parent\u002Fguardian must be willing to avoid travel, particularly in the 28 days after each study vaccination, must confirm willingness to contact the study team in the event of unexpected\u002Funavoidable travel and, for the safety cohort, must confirm availability for the home visits to be conducted by a field worker or nurse to collect solicited AEs over the 7 days (day of vaccination and 6 subsequent days) following each study vaccine.\n* The participant's parent\u002Fguardian must confirm willingness to bring their child to the study clinic \u002F local health care clinic, and capacity to contact the study team in the event the subject has any illnesses or other health concerns during the study.\n* Participants who the investigator believes that their parent\u002Fguardian can and will comply with the requirements of the protocol (e.g. return for follow-up visits) may be enrolled in the study.\n\nExclusion Criteria:\n\n• Acute disease at the time of enrolment (acute disease is defined as the presence of a moderate or severe illness with or without fever). This does not include minor illnesses such as diarrhea, mild upper respiratory infection, without low-grade febrile illness, i.e. axillary temperature \\\u003C 37.5°C or tympanic temperature \\\u003C 38°C.\n\n(Note: In case of acute disease, participants may be re-assessed by a study physician for resolution of the condition and enrolled if eligible and still within the visit window).\n\n* Clinically significant pulmonary, cardiovascular, gastrointestinal, endocrine, neurological, skin, hepatic or renal functional abnormality, as determined by medical history, physical examination or laboratory tests which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial.\n* At time of enrollment, any infant who has received any dose of the hexavalent\u002Fpentavalent vaccines, pneumococcal vaccine, rotavirus vaccine, IPV or has received more than one dose of oral polio virus or more than one dose of hepatitis B vaccine.\n* Weight-for-length\u002Fheight Z score of less than -3 or other clinical signs of malnutrition.\n* Infant with major congenital defects.\n* The infant has anaemia associated with clinical signs of symptoms of decompensation, or a haemoglobin of ≤ 5.0 g\u002FdL.\n* History of allergic disease or reactions likely to be exacerbated by any component of the vaccines.\n* Any confirmed or suspected immunosuppressive or immunodeficient state (including HIV or asplenia) or known maternal HIV infection (no HIV testing will be routinely done by the study team).\n* Administration of immunoglobulins and\u002For any blood products\u002Fblood transfusion from birth to time of planned administration of the vaccine candidate.\n* Previous vaccination of participant or biological mother with a malaria vaccine.\n* Participation in another research study involving receipt of an investigational product or planned use during the study period.\n* Any other findings that the investigator feels would increase the risk of having an adverse outcome from participation in the trial.",true,"ALL","42 Days","49 Days",{"count":183,"type":184},964,"ESTIMATED","INTERVENTIONAL",[187],"PHASE2","The aim of this study is to identify an optimal infant vaccine schedule for a malaria vaccine which is better aligned with the timing of other vaccine interventions.",[190],"Malaria Vaccines",[192,193],"Plasmodium falciparum","R21\u002FMatrix-M Malaria Vaccine","2026-05-13",{"date":196,"type":197},"2026-05-15","ACTUAL",{"date":199,"type":197},"2025-05-30",{"date":201,"type":184},"2027-09-27",{"name":5,"class":6},2]